IRLAB Therapeutics

Edison Investment Research has terminated coverage on IRLAB Therapeutics (IRLAB-A). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: The ageing society – a structural shift investors cannot ignore

Edison explains: Rare earth elements – can the world break China’s grip on rare earths?

Decarbonising the built environment – Steel and cement in focus

Audiovisual

Latest

BB Biotech in 60 seconds

Global Fashion Group – executive interview

Trade Estates – equity proposition

About Edison

Corporates

Investors

Careers

IRLAB Therapeutics (OMX: IRLAB-A)

Latest Insights

IRLAB Therapeutics — Next steps laid out for IRL757

IRLAB (OMX: IRLAB-A) publishes preclinical mesdopetam data in journal

IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study

IRLAB Therapeutics (OMX: IRLAB-A) misses primary endpoint with pirepemat

Sector

Equity Analyst

Key Management

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — New mesdopetam patent strengthens IP portfolio

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Anticipation builds as inflection points approach

IRLAB Therapeutics — Pirepemat passes Phase IIb DSMB safety hurdle

IRLAB Therapeutics — Mesdopetam disease-modifying potential

IRLAB Therapeutics — Valuation uplift supported by IRL757

IRLAB Therapeutics — External validation boosts quarterly recap

IRLAB Therapeutics — MSRD agreement early validation for IRL757

IRLAB Therapeutics — Beyond PD-LID, a closer look at PD-psychosis

IRLAB Therapeutics — FDA thumbs up to mesdopetam’s Phase III plan

IRLAB Therapeutics — Mesdopetam’s potential highlighted in PD-psychosis

IRLAB Therapeutics — Positive FDA mesdopetam outlook following EoP2

IRLAB Therapeutics — Timeline refresh with numerous inflection points

IRLAB Therapeutics — End-of-Phase II FDA meeting set

IRLAB Therapeutics — SEK55m loan enhances headroom past key catalysts

IRLAB Therapeutics — IRL757 Phase I-ready with support from MJFF

IRLAB Therapeutics — Mesdopetam’s clinical roadmap laid out

IRLAB Therapeutics — Increased legroom for pirepemat with new patent

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Quarterly update recapping active pipeline plans

IRLAB Therapeutics — Collaboration to support FDA Ph III progression

IRLAB Therapeutics — Numerous clinical platform activities under way

IRLAB Therapeutics — Despite shift, mesdopetam still on track for Ph III

IRLAB Therapeutics — Phase IIb pirepemat obtains safety milestone

IRLAB Therapeutics — On track for pirepemat in Phase IIb

IRLAB Therapeutics — Collaboration bolsters CNS assets and platform

IRLAB Therapeutics — Positive signs for mesdopetam in Q1 update

IRLAB Therapeutics — Mesdopetam remains in Ipsen’s portfolio

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Don’t count mesdopetam out

IRLAB Therapeutics — Cautious update on portfolio timelines

IRLAB Therapeutics — Mesdopetam Phase IIb top-line data

IRLAB Therapeutics — Candidate selected to further bolster pipeline

IRLAB Therapeutics — Phase IIb trial patient follow-up as expected

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Mesdopetam top-line data readout approaches

IRLAB Therapeutics — Phase IIb recruitment complete

IRLAB Therapeutics — Ipsen confirms commitment with clinical studies

IRLAB Therapeutics — All steady as key catalyst approaches

IRLAB Therapeutics — Phase IIb/III mesdopetam study expanded

IRLAB Therapeutics — Clinical pipeline is tip of the iceberg

IRLAB Therapeutics — Richard Godfrey appointed as new CEO

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Screening platform continues to bear fruit

IRLAB Therapeutics — Looking beyond mesdopetam

IRLAB Therapeutics — Pirepemat and platform potential come into focus

IRLAB Therapeutics AB: Edison Open House Healthcare 2022

IRLAB Therapeutics — Platform validated, pipeline momentum building

IRLAB Therapeutics — Platform validated, pipeline momentum building

IRLAB Therapeutics — Ipsen deal de-risks the strategy

IRLAB Therapeutics — Global licensing deal for mesdopetam

IRLAB Therapeutics — Focused on novel Parkinson’s disease treatments